Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.'s Dru... (f ZEVALIN aradiopharmaceutical which CTI...)

Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.'s Drug Pipeline

Date:11/14/2007

f ZEVALIN, a radiopharmaceutical which CTI has agreed to acquire from Biogen Idec. Commenting on the slow adoption of ZEVALIN by doctors, Dr. Hagemeister said that increased adoption of ZEVALIN may be more likely if the clinical data supporting its use "becomes so compelling that physicians will administer ZEVALIN as a follow-up drug in consolidation. While I don't know the FIT trial data, it would appear those results may provide such a compelling reason given that the study was closed early because of the significant benefit on progression-free survival in patients who received ZEVALIN as consolidation therapy."

Bayer HealthCare, the sponsor of the ZEVALIN FIT trial (First-line Indolent Trial), a multinational, randomized phase III trial of ZEVALIN after first-line induction chemotherapy, recently announced that the trial met its primary endpoint - demonstrating an improvement in progression-free survival (PFS). The results of this trial will be presented in an oral presentation (abstract #643) on Monday, Dec. 10, 2007 at the 49th Annual Meeting of the American Society of Hematology (ASH) in Atlanta. CTI's acquisition of ZEVALIN remains subject to closing conditions, including obtaining certain third party consents, and until the acquisition is closed, ZEVALIN remains a product and trademark of Biogen Idec.

Pixantrone (BBR 2778)

Peter Borchmann, M.D., Ph.D., Senior Consultant of Hematology and Oncology at the University Hospital of Cologne, reviewed the phase I and II studies of pixantrone and the strong rationale for the design of the ongoing phase III studies in non-Hodgkin's lymphoma (NHL). "Having worked with pixantrone for the past nine years, I am delighted to see CTI invest in completing the phase III trials to establish the efficacy, overall safety, and cardiac safety profile of pixantrone. In our experience in the early clinical study results of pixantrone, we've seen low incidences of cardiotoxicity despite prior anthracycline exposure
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine news :

1. Radiologists encouraged to look beyond cancer for clinically unseen diseases
2. Clinical depression linked to abnormal emotional brain circuits
3. Preclinical study suggests organ-transplant drug may aid in lupus fight
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Good Clinical Practice Journal Awards: Winners Announced
6. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
7. Study Questions Dead-End Cancer Clinical Trials
8. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
9. Clinical trials present better alternatives for dialysis patients
10. Mirixa Debuts New Clinical Technology Solutions for Enhancing Patient Care
11. IMPACT initiative looks to improve patient participation in clinical trials

Post Your Comments:

Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.'s Dru...(f ZEVALIN aradiopharmaceutical which CTI...),Health